References
- Espin J, Rovira J, de Labry AO, et al. WHO/HAI project on medicine prices and availability, review series on pharmaceutical pricing policies and interventions. WHO Health Action Int 2011
- Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev Pharmacoecon Outcomes Res 2010;10(3):239-45
- Folino-Gallo P, Montilla S, Bruzzone M, et al. Pricing and reimbursement of pharmaceuticals in Italy. Eur J Health Econ 2008;9(3):305-10
- Håkonsen H, Horn AM, Toverud EL. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004? Health Policy 2009;90(2-3):277-85
- Leopold C, Vogler S, Mantel-Teeuwisse AK, et al. Differences in external price referencing in Europe: a descriptive overview. Health Policy 2012;104(1):50-60
- Merkur S, Mossialos E. A pricing policy towards the sourcing of cheaper drugs in Cyprus. Health Policy 2007;81(2-3):368-75
- Mrazek MF. Comparative approaches to pharmaceutical price regulation in the European Union. Croat Med J 2002;43(4):453-61
- Stargardt T, Schreyögg J. Impact of cross-reference pricing on pharmaceutical prices: manufacturers’ pricing strategies and price regulation. Appl Health Econ Health Policy 2006;5(4):235-47
- Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. European Economy - Economic Papers 461, Directorate General Economic and Monetary Affairs (DG ECFIN). Eur Commission 2012
- Leopold C, Mantel-Teeuwisse AK, Vogler S, et al. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 2013;112(3):209-16
- External Reference Pricing. Europe economics. 2013. Available from: www.europe-economics.com/publications/external_reference_pricing_-_final_report.pdf [Last accessed 20 April 2015]
- Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(6):735-41
- Danzon PM, Towse A, Mulcahy AW. Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Aff (Millwood) 2011;30(8):1529-38
- Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s. Health Econ 2005;14(3):269-92
- Kanavos P, Nicod E, Espin J, et al. Short- and long-term effects of value-based pricing vs. external price referencing. EmiNet, European Commission. 2010. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/valuebased_pharmapricing_012010_en.pdf [Last accessed 8 December 2014]
- Garau M, Towse A, Danzon P. Pharmaceutical pricing in Europe: is differential pricing a win-win solution? Occasional Paper 11/01. Office of Health Economics; London: 2011
- IMF World Economic Outlook Database. 2013. Available from: www.imf.org/external/pubs/ft/weo/2013/01/weodata/index.aspx
- WHO Global Health Observatory. Available from: www.who.int/gho/countries/en/